Observational Studies of Statins in Systolic Heart Failure
This article reviews the results of observational statin use in clinical trials of patients who have systolic heart failure, in post-myocardial infarction with left ventricular dysfunction, and in cardiac device trials. This article shows a consistent benefit of statins on mortality (approximately 25%) in heart failure patients of both ischemic and nonischemic etiology. The benefit is not altered by concomitant heart failure medications or device therapy. The benefit of statins in heart failure is being investigated in large prospective trials in a broad range of heart failure patients.
University of Washington, Seattle, WA, USA
Division of Cardiology, University of Washington, Box 356422, 1959 NE Pacific Street, Seattle, WA 98195.
Dr. Levy has consulted for or participated in speakers bureaus for the following companies in the last 12 months: Pfizer, GlaxoSmithKline, Novartis, BoehringerIngelheim, Thoratec, and Medtronic. He serves on the steering committee for clinical trials by Amgen and Scios. He is on the end point committee for clinical trials by General Electric. He has received research funding from Scios, Medtronic, Vasogen, Astellas, and Thoratec. He has equity in Cardiac Dimensions. The University of Washington holds the copyright for the Seattle Heart Failure Model.
ABSTRACT